• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨保护素和核因子-κB 受体活化因子配体在类风湿关节炎相关性骨质疏松症发病机制中的作用。

Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis.

机构信息

Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, No 218 Jixi Street, Hefei 230022, China.

出版信息

Rheumatol Int. 2012 Nov;32(11):3397-403. doi: 10.1007/s00296-011-2175-5. Epub 2011 Nov 6.

DOI:10.1007/s00296-011-2175-5
PMID:22057136
Abstract

Osteoporosis represents an important cause of morbidity in adult rheumatoid arthritis (RA) patients who exhibit increased fracture risk. It is thought that osteoclast and its dysfunction which mediated by many cytokines are the principal pathogenesis of this bone disease, although the mechanisms are still not fully understood. Osteoprotegerin (OPG) and receptor activator of nuclear factor-kappa B ligand (RANKL) have been revealed in the pathogenesis of primary osteoporosis and other metabolic bone diseases. Thus, the aim of this study was to investigate the possible role of the OPG/RANKL system in RA-related bone loss. A total of 64 Chinese patients with RA and 60 healthy control subjects were involved. Serum levels of OPG and RANKL were measured by ELISA. BMD of nondominant forearm, lumbar spine(L(1-4)) and proximal femur, including femoral neck, Wards triangle, greater trochanter were assessed using dual-energy X-ray absorptiometry. RA patients had a higher incidence of osteoporosis (23/64, 35.9%) than that in healthy controls (9/60, 15.0%) (P < 0.0001). They displayed lower BMD values than controls at positions of all detected region. Compared with healthy controls, RA group showed significantly higher serum levels of RANKL (48.4 ± 12.5 vs. 23.0 ± 11.2 pmol/l, P < 0.0001), lower serum levels of OPG (106.2 ± 40.6 vs. 231.6 ± 65.6 pg/ml, P < 0.0001), and OPG/RANKL ratio (2.4 ± 0.7 vs. 7.0 ± 1.1, P < 0.0001). Multiple linear regression analysis revealed that in RA group, plasma rheumatoid factor concentration (β = -0.187, P = 0.031), swollen joint count (β = 0.567, P = 0.029), BMD at forearm (β = 0.324, P = 0.002), femoral Wards triangle (β = 0.370, P < 0.0001), and lumbar spine (β = 0.313, P = 0.003) were the contributors for serum OPG (R ( 2 ) = 0.718, P < 0.0001). Age (β = 0.241, P = 0.042) and BMD at femoral Wards triangle (β = -0.441, P < 0.0001) and lumbar spine (β = -0.320, P = 0.013) were the determinants for serum RANKL (R ( 2 ) = 0.616, P < 0.0001), while swollen joint count (β = 1.029, P = 0.019) and BMD at femoral neck (β = 0.285, P = 0.042) for serum OPG/RANKL ratio (R ( 2 ) = 0.279, P < 0.011). Analysis of logistic regression showed age (P = 0.004, OR = 1.156, 95% CI: 1.047-1.276) and the level of C-reactive protein (P = 0.028, OR = 1.019, CI 95%: 1.002-1.036) in peripheral blood of RA were the risk factors for the occurrence of osteoporosis in RA, while OPG/RANKL ratio (P = 0.007, OR = 0.035, CI 95%: 0.003-0.400) was the unique protective factor. These data suggest that, in Chinese RA patients, an altered modulation of the OPG/RANKL system resulting in increased RANKL and decreased OPG in peripheral blood, could contribute to the bone loss characteristic and the generation of osteoporosis in these patients. Changes of ratio of OPG/RANKL might be a protective mechanism against the accelerated bone loss in RA.

摘要

骨质疏松症是成年类风湿关节炎(RA)患者的一个重要发病原因,此类患者骨折风险增加。人们认为破骨细胞及其介导的许多细胞因子功能障碍是这种骨病的主要发病机制,尽管其机制尚不完全清楚。骨保护素(OPG)和核因子-κB 配体受体激活剂(RANKL)已被发现参与原发性骨质疏松症和其他代谢性骨疾病的发病机制。因此,本研究旨在探讨 OPG/RANKL 系统在 RA 相关骨丢失中的可能作用。共纳入 64 例中国 RA 患者和 60 例健康对照者。采用酶联免疫吸附法(ELISA)检测血清 OPG 和 RANKL 水平。采用双能 X 线吸收法(DXA)检测非优势前臂、腰椎(L(1-4))和股骨近端,包括股骨颈、Wards 三角区、大转子的骨密度(BMD)。RA 患者骨质疏松症的发生率(23/64,35.9%)明显高于健康对照组(9/60,15.0%)(P<0.0001)。与健康对照组相比,RA 组在所有检测部位的 BMD 值均较低。与健康对照组相比,RA 组血清 RANKL 水平显著升高(48.4±12.5 vs. 23.0±11.2 pmol/L,P<0.0001),OPG 水平显著降低(106.2±40.6 vs. 231.6±65.6 pg/ml,P<0.0001),OPG/RANKL 比值降低(2.4±0.7 vs. 7.0±1.1,P<0.0001)。多元线性回归分析显示,在 RA 组中,血浆类风湿因子浓度(β=-0.187,P=0.031)、肿胀关节数(β=0.567,P=0.029)、前臂 BMD(β=0.324,P=0.002)、股骨 Ward 三角区 BMD(β=0.370,P<0.0001)和腰椎 BMD(β=0.313,P=0.003)是血清 OPG 的影响因素(R2=0.718,P<0.0001)。年龄(β=0.241,P=0.042)和股骨 Ward 三角区 BMD(β=-0.441,P<0.0001)和腰椎 BMD(β=-0.320,P=0.013)是血清 RANKL 的决定因素(R2=0.616,P<0.0001),而肿胀关节数(β=1.029,P=0.019)和股骨颈 BMD(β=0.285,P=0.042)是血清 OPG/RANKL 比值的决定因素(R2=0.279,P<0.011)。Logistic 回归分析显示,年龄(P=0.004,OR=1.156,95%CI:1.047-1.276)和外周血 C 反应蛋白水平(P=0.028,OR=1.019,CI 95%:1.002-1.036)是 RA 患者发生骨质疏松症的危险因素,而 OPG/RANKL 比值(P=0.007,OR=0.035,CI 95%:0.003-0.400)是唯一的保护因素。这些数据表明,在中国 RA 患者中,外周血中 OPG/RANKL 系统的异常调节导致 RANKL 增加和 OPG 减少,可能导致这些患者的骨丢失和骨质疏松症的发生。OPG/RANKL 比值的变化可能是 RA 患者加速骨丢失的一种保护机制。

相似文献

1
Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis.骨保护素和核因子-κB 受体活化因子配体在类风湿关节炎相关性骨质疏松症发病机制中的作用。
Rheumatol Int. 2012 Nov;32(11):3397-403. doi: 10.1007/s00296-011-2175-5. Epub 2011 Nov 6.
2
Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle.骨保护素和核因子κB受体活化因子配体在 thalassemia 诱导的骨质疏松症发病机制中的作用:谜题的新线索。
J Bone Miner Res. 2004 May;19(5):722-7. doi: 10.1359/JBMR.040113. Epub 2004 Jan 12.
3
Assessment of Serum sRANKL, sRANKL/OPG Ratio, and Other Bone Turnover Markers with the Estimated 10-Year Risk of Major and Hip Osteoporotic Fractures in Rheumatoid Arthritis: A Cross-Sectional Study.评估类风湿关节炎患者血清 sRANKL、sRANKL/OPG 比值和其他骨转换标志物与 10 年主要和髋部骨质疏松性骨折风险的相关性:一项横断面研究。
Biomed Res Int. 2021 Aug 30;2021:5567666. doi: 10.1155/2021/5567666. eCollection 2021.
4
Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.1型糖尿病儿童和青少年中较高水平的可溶性核因子κB受体活化因子配体(s-RANKL)和骨保护素可能表明破骨细胞信号增加以及骨量降低的易感性:一项多变量横断面分析。
Osteoporos Int. 2016 Apr;27(4):1631-1643. doi: 10.1007/s00198-015-3422-5. Epub 2015 Nov 20.
5
The balance between soluble receptors regulating IL-6 trans-signaling is predictive for the RANKL/osteoprotegerin ratio in postmenopausal women with rheumatoid arthritis.可溶性受体调节白介素 6 转导信号的平衡可预测绝经后类风湿关节炎患者的 RANKL/骨保护素比值。
Rheumatol Int. 2012 Jan;32(1):199-206. doi: 10.1007/s00296-010-1606-z. Epub 2010 Sep 7.
6
Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.绝经后女性血清核因子-κB 受体活化因子配体、骨保护素、高敏 C 反应蛋白与骨密度之间的关系:骨免疫与骨炎症
Menopause. 2009 Sep-Oct;16(5):950-5. doi: 10.1097/gme.0b013e3181a181b8.
7
Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.骨保护素和核因子κB受体活化因子配体在重型地中海贫血患者骨质疏松发病机制中的作用
Panminerva Med. 2009 Mar;51(1):17-23.
8
Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover.类风湿关节炎中可溶性核因子κB受体活化因子配体与骨保护素——与骨密度、疾病活动度及骨转换的关系
Clin Rheumatol. 2007 Dec;26(12):2127-2135. doi: 10.1007/s10067-007-0639-5. Epub 2007 May 31.
9
Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis.COPD 肺气肿伴骨质疏松患者中 OPG/RANK/RANKL 通路紊乱与全身炎症反应。
Respir Res. 2011 Dec 16;12(1):157. doi: 10.1186/1465-9921-12-157.
10
Single nucleotide polymorphism of RANKL and OPG genes may play a role in bone and joint injury in rheumatoid arthritis.RANKL和OPG基因的单核苷酸多态性可能在类风湿关节炎的骨关节损伤中起作用。
Clin Exp Rheumatol. 2014 Sep-Oct;32(5):697-704. Epub 2014 Jul 17.

引用本文的文献

1
High Dietary Phosphorus Impairs Bone Microarchitecture and Induces Alterations in the LGR4-R-Spondins Axis in Rats with Normal Renal Function.高磷饮食损害肾功能正常大鼠的骨微结构并诱导LGR4-R-促调蛋白轴的改变。
Nutrients. 2025 Jun 19;17(12):2049. doi: 10.3390/nu17122049.
2
OPG/RANK/RANKL Single-Nucleotide Polymorphisms in Rheumatoid Arthritis: Associations with Disease Susceptibility, Bone Mineral Density, and Clinical Manifestations in a Chinese Han Population.类风湿关节炎中OPG/RANK/RANKL单核苷酸多态性:中国汉族人群中与疾病易感性、骨密度及临床表现的关联
Int J Gen Med. 2025 Feb 17;18:815-824. doi: 10.2147/IJGM.S506743. eCollection 2025.
3

本文引用的文献

1
Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.地诺单抗对类风湿关节炎结构损伤、骨密度和骨转换的治疗效果:一项为期十二个月的多中心、随机、双盲、安慰剂对照的II期临床试验。
Arthritis Rheum. 2008 May;58(5):1299-309. doi: 10.1002/art.23417.
2
Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover.类风湿关节炎中可溶性核因子κB受体活化因子配体与骨保护素——与骨密度、疾病活动度及骨转换的关系
Clin Rheumatol. 2007 Dec;26(12):2127-2135. doi: 10.1007/s10067-007-0639-5. Epub 2007 May 31.
3
Genetic Variants in RANK and OPG Could Influence Disease Severity and Bone Remodeling in Patients with Early Arthritis.
RANK和OPG基因变异可能影响早期关节炎患者的疾病严重程度和骨重塑。
Life (Basel). 2024 Sep 3;14(9):1109. doi: 10.3390/life14091109.
4
Novel Biomarkers of Bone Metabolism.新型骨代谢生物标志物。
Nutrients. 2024 Feb 22;16(5):605. doi: 10.3390/nu16050605.
5
Muscle-bone crosstalk via endocrine signals and potential targets for osteosarcopenia-related fracture.通过内分泌信号的肌肉-骨骼相互作用以及骨质疏松性肌少症相关骨折的潜在靶点
J Orthop Translat. 2023 Nov 5;43:36-46. doi: 10.1016/j.jot.2023.09.007. eCollection 2023 Nov.
6
The association of osteoprotegerin and RANKL with osteoporosis: a systematic review with meta-analysis.骨保护素和核因子-κB 受体活化因子配体与骨质疏松症的相关性:系统评价与荟萃分析。
J Orthop Surg Res. 2023 Nov 7;18(1):839. doi: 10.1186/s13018-023-04179-5.
7
Positive Effects of Biologics on Osteoporosis in Rheumatoid Arthritis.生物制剂对类风湿关节炎骨质疏松症的积极作用。
J Rheum Dis. 2023 Jan 1;30(1):3-17. doi: 10.4078/jrd.22.0046.
8
Fractionated whole body γ-irradiation aggravates arthritic severity via boosting NLRP3 and RANKL expression in adjuvant-induced arthritis model: the mitigative potential of ebselen.分次全身γ射线照射通过增强佐剂诱导关节炎模型中 NLRP3 和 RANKL 的表达加重关节炎严重程度:依布硒啉的缓解潜力。
Inflammopharmacology. 2023 Aug;31(4):1929-1949. doi: 10.1007/s10787-023-01238-5. Epub 2023 May 2.
9
Low-Level Laser Therapy for Rheumatoid Arthritis: A Review of Experimental Approaches.类风湿关节炎的低强度激光治疗:实验方法综述
J Lasers Med Sci. 2022 Dec 10;13:e62. doi: 10.34172/jlms.2022.62. eCollection 2022.
10
Pathomechanisms of bone loss in rheumatoid arthritis.类风湿关节炎中骨质流失的发病机制。
Front Med (Lausanne). 2022 Aug 17;9:962969. doi: 10.3389/fmed.2022.962969. eCollection 2022.
Epidemiology of osteoporosis in rheumatic diseases.风湿性疾病中骨质疏松症的流行病学
Rheum Dis Clin North Am. 2006 Nov;32(4):631-58. doi: 10.1016/j.rdc.2006.07.002.
4
RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes.在类风湿性滑膜炎和淋巴结的配对样本中,RANK和RANKL表达作为树突状细胞与T细胞相互作用的标志物。
Arthritis Rheum. 2005 Aug;52(8):2307-12. doi: 10.1002/art.21211.
5
Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis.血清和滑液中的骨保护素及核因子κB受体活化因子配体。长期类风湿关节炎患者与骨关节炎患者的比较。
Rheumatol Int. 2005 Nov;26(1):63-9. doi: 10.1007/s00296-004-0579-1. Epub 2005 May 12.
6
Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density.类风湿关节炎患者的骨密度:疾病严重程度与低骨密度之间的关系。
Ann Rheum Dis. 2004 Dec;63(12):1576-80. doi: 10.1136/ard.2003.016253.
7
TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis.肿瘤坏死因子-α抗体和骨保护素通过不同机制减少胶原诱导性关节炎中与炎症相关的全身性骨质流失。
Bone. 2004 Nov;35(5):1200-7. doi: 10.1016/j.bone.2004.07.004.
8
TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis.1型肿瘤坏死因子受体调节基质细胞的核因子κB受体活化因子配体表达并调节破骨细胞生成。
J Cell Biochem. 2004 Nov 15;93(5):980-9. doi: 10.1002/jcb.20197.
9
Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls.类风湿关节炎患者与健康对照者中骨保护素及核因子-κB受体激活剂配体mRNA的表达
J Rheumatol. 2004 Aug;31(8):1483-90.
10
Role for osteoprotegerin in rheumatoid inflammation.骨保护素在类风湿性炎症中的作用。
Joint Bone Spine. 2004 Jan;71(1):9-13. doi: 10.1016/S1297-319X(03)00131-3.